预约演示

更新于：2025-07-29

Descartes-08

更新于：2025-07-29

概要

概要

基本信息

药物类型

自体CAR-T、mRNA CAR-T

别名

Anti-BCMA CAR-T cell therapy、Anti-BCMA chimeric antigen receptor T cell therapy、autologous T-cells expressing a chimeric antigen receptor directed against B-Cell maturation antigen

+ [2]

靶点

BCMA

作用方式

抑制剂

作用机制

BCMA抑制剂(B细胞成熟蛋白抑制剂)

治疗领域

肿瘤免疫系统疾病神经系统疾病+ [3]

在研适应症

重症肌无力系统性红斑狼疮抗中性粒细胞胞质抗体相关性血管炎+ [1]

非在研适应症

多发性骨髓瘤

原研机构-

在研机构

Cartesian Therapeutics, Inc.

非在研机构-

权益机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、再生医学先进疗法 (美国)、罕见儿科疾病 (美国)

登录后查看时间轴

关联

项与 Descartes-08 相关的临床试验

NCT07089121

/ Not yet recruiting临床1/2期

DESCARTES-08 FOR CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH AUTOIMMUNE DISORDERS

Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis

开始日期2025-12-01

申办/合作机构

Cartesian Therapeutics, Inc.

NCT06799247

/ Recruiting临床3期

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Descartes-08 in Patients With Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis

The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.

开始日期2025-05-06

申办/合作机构

Cartesian Therapeutics, Inc.

NCT06038474

/ Recruiting临床2期

Descartes-08 for Patients With Systemic Lupus Erythematosus

This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).

开始日期2024-02-12

申办/合作机构

Cartesian Therapeutics, Inc.

100 项与 Descartes-08 相关的临床结果

登录后查看更多信息

100 项与 Descartes-08 相关的转化医学

登录后查看更多信息

100 项与 Descartes-08 相关的专利（医药）

登录后查看更多信息

项与 Descartes-08 相关的文献（医药）

2023-07-01·The Lancet. Neurology

Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

Article

作者: Miljković, Miloš D ; Slansky, Adam D. ; Pereira, Denise ; Brooks, Beverly Mackanzie ; Chowdhury, Adam ; Mozaffar, Tahseen ; Steele, Julie ; Tosun, Mehmet ; Habib, Ali Aamer ; Kurtoglu, Metin ; Singer, Michael S ; Jewell, Christopher M. ; Duvernay, Matthew T. ; DeMaria, Gabrielle ; Farias, Jerrica ; Requena, Naraly ; English, Emily ; Chahin, Nizar ; Benatar, Michael ; Vu, Tuan ; Howard, James F ; Feinberg, Marc H ; Suresh, Niraja ; Kamboh, Hafsa ; Komanduri, Krishna ; Benjamin, Cara ; Slansky, Adam ; Kireeva, Maria ; Jewell, Christopher M ; Sahagian, Gregory ; Granit, Volkan ; Dimitrova, Diana ; Howard, James F. ; Holley, Kelly ; Daniel, Shaji ; Ngo Casi, Minhtran ; De La Cruz, Luis ; Kalayoglu, Murat V ; Tenorio, April ; Chopra, Manisha ; Shan, Yufei ; Fong, Julia Kimberly ; Stewart, C Andrew ; Feinberg, Marc H. ; Paredes, Maria Elena

BACKGROUND:

Chimeric antigen receptor (CAR) T cells are highly effective in treating haematological malignancies, but associated toxicities and the need for lymphodepletion limit their use in people with autoimmune disease. To explore the use of CAR T cells for the treatment of people with autoimmune disease, and to improve their safety, we engineered them with RNA (rCAR-T)-rather than the conventional DNA approach-to target B-cell maturation antigen (BCMA) expressed on plasma cells. To test the suitability of our approach, we used rCAR-T to treat individuals with myasthenia gravis, a prototypical autoantibody disease mediated partly by pathogenic plasma cells.

METHODS:

MG-001 was a prospective, multicentre, open-label, phase 1b/2a study of Descartes-08, an autologous anti-BCMA rCAR-T therapy, in adults (ie, aged ≥18 years) with generalised myasthenia gravis and a Myasthenia Gravis Activities of Daily Living (MG-ADL) score of 6 or higher. The study was done at eight sites (ie, academic medical centres or community neurology clinics) in the USA. Lymphodepletion chemotherapy was not used. In part 1 (phase 1b), participants with Myasthenia Gravis Foundation of America (MGFA) disease class III-IV generalised myasthenia gravis received three ascending doses of Descartes-08 to determine a maximum tolerated dose. In part 2 (phase 2a), participants with generalised myasthenia gravis with MGFA disease class II-IV received six doses at the maximum tolerated dose in an outpatient setting. The primary objective was to establish safety and tolerability of Descartes-08; secondary objectives were to assess myasthenia gravis disease severity and biomarkers in participants who received Descartes-08. This trial is registered with clinicaltrials.gov, NCT04146051.

FINDINGS:

We recruited 16 individuals for screening between Jan 7, 2020 and Aug 3, 2022. 14 participants were enrolled (n=3 in part 1, n=11 in part 2). Ten participants were women and four were men. Two individuals did not qualify due to low baseline MG-ADL score (n=1) or lack of generalised disease (n=1). Median follow-up in part 2 was 5 months (range 3-9 months). There was no dose-limiting toxicity, cytokine release syndrome, or neurotoxicity. Common adverse events were headache (six of 14 participants), nausea (five of 14), vomiting (three of 14), and fever (four of 14), which resolved within 24 h of infusion. Fevers were not associated with increased markers of cytokine release syndrome (IL-6, IL-2, and TNF). Mean improvements from baseline to week 12 were -6 (95% CI -9 to -3) for MG-ADL score, -7 (-11 to -3) for Quantitative Myasthenia Gravis score, -14 (-19 to -9) for Myasthenia Gravis Composite score, and -9 (-15 to -3) for Myasthenia Gravis Quality of Life 15-revised score.

INTERPRETATION:

In this first study of an rCAR-T therapy in individuals with an autoimmune disease, Descartes-08 appeared to be safe and was well tolerated. Descartes-08 infusions were followed by clinically meaningful decreases on myasthenia gravis severity scales at up to 9 months of follow-up. rCAR-T therapy warrants further investigation as a potential new treatment approach for individuals with myasthenia gravis and other autoimmune diseases.

FUNDING:

Cartesian Therapeutics and National Institute of Neurological Disorders and Stroke of the National Institutes of Health.

105

项与 Descartes-08 相关的新闻（医药）

2025-06-23

·生物制药小编

CAR-T成功治愈神经自免罕见病

近期，先后有两篇报道表明CAR-T可以治愈一种罕见神经自免疾病——慢性炎症性脱髓鞘性多发性神经病（CIDP）。其中一篇来自于华中科技大学同济医院的研究（5月发表于《Cell》），另外一篇来自于德国北莱茵-威斯特法伦州鲁尔大学波鸿分校附属医院的研究（发表于《柳叶刀·神经病学》）。双方分别采用了CD19和BCMA两种靶向不同的CAR-T分别证明了CAR-T治疗该疾病的有效性。这是全球首批关于CAR T细胞疗法用于治疗严重自身免疫性神经病变的临床报告。机制机理CIDP是一种典型的自身免疫性疾病，其根本病因是免疫系统错误地将周围神经系统的髓鞘识别为“外来入侵者”，并发动攻击。例如，B淋巴细胞在CIDP患者中异常活跃，会产生针对髓鞘蛋白（如P0、P2）的自身抗体，或通过分泌促炎细胞因子（如IL-6、TNF-α）直接破坏髓鞘。而髓鞘破坏就会导致肢体无力、感觉异常（如麻木、针刺感），严重时可致呼吸肌麻痹，最终导致死亡。更关键的是，15%的CIDP患者对传统疗法（如激素、免疫球蛋白）无效，且疾病呈慢性进展性。在波鸿中的两例患者都尝试了各种各样的免疫疗法，如静脉免疫球蛋白、皮质类固醇、血浆置换、环磷酰胺、利妥昔单抗、obinutuzumab和硼替佐米等等，但最终因为疾病的难治性都不得不转向CAR-T治疗方案。CAR-T可以通过靶向B细胞表面特异性抗原（如BCMA和CD19），可以直接清除致病性的B淋巴细胞，为神经修复创造条件。治疗状况华中科技大学同济医院的案例中纳入了两名高度难治性CIDP患者，均为男性，年龄分别为52岁和63岁。两名患者均经历多次疾病复发，且接受多种免疫治疗后效果不佳，存在严重功能障碍。两名患者体内的CAR-T细胞均成功扩增，并在输注后10天达到峰值，且能在体内持续存在至少6个月。输注后，两名患者均出现持续约2个月的B细胞谱系完全清除，自身抗体水平可能有所下降。输注后6个月内，两名患者均实现无药缓解，神经功能显著改善，可生活自理。具体表现为肌力提高、感觉障碍减轻、日常生活能力提高等。患者1在由于受到新冠感染再激活B细胞导致注输12个月后复发，患者2则维持24个月持续缓解。波鸿团队的案例中同样纳入了两名难治性CIDP，患者1为72岁男性，患者2为54岁男性。输注后，两名患者均出现显著的临床改善。患者1从间歇性不动改善为进行深蹲和引体向上，炎症性神经病变指标（如总体残疾评分、步行距离和血清神经丝轻链浓度）均有显著改善。患者2的神经功能也有显著改善，具体表现为行走能力提高、感觉功能恢复等。图：治疗10个月后，患者1已经可以自由走动两名患者均出现轻至中度细胞因子释放综合征，但通过tocilizumab和皮质类固醇治疗得到缓解。患者1还出现1级免疫效应细胞相关神经毒性综合征，此后完全缓解。总结此次关于CIDP的CAR-T研究似乎正在揭开重症自身免疫疾病治疗的新篇章。未来可以看到华中科技大学同济医院和波鸿大学医院的更多临床案例，可能将适应症扩展到重症肌无力、僵人综合征等疾病上。参考来源：Jeremias Motte et al, CD19-targeted CAR T-cell therapy for treatment-refractory autoimmune neuropathies, The Lancet Neurology (2025). DOI: 10.1016/S1474-4422(25)00199-1Dong, Ming-Hao et al. “Anti-BCMA CAR-T cell therapy in relapsed/refractory chronic inflammatory demyelinating polyneuropathy.” Med (New York, N.Y.), 100704. 16 May. 2025.

免疫疗法细胞疗法临床结果临床研究

2025-06-17

·医药观澜

寻找“治愈”曙光：7款新药已获批上市，下一代重症肌无力疗法有望迎来新突破

编者按：刚刚过去的“全球重症肌无力关爱日”再次提醒大家关注这一罕见疾病。重症肌无力（MG）是一种罕见的神经肌肉-自身免疫性疾病，会导致患者虚弱和可能危及生命的肌无力。目前该疾病尚无治愈方法。随着研究进展和产业持续投入，近十年来多款针对重症肌无力的创新药获监管机构批准上市，极大改善了患者的生活。与此同时，全球更多MG新药管线已进入临床阶段，涵盖抗体疗法、siRNA药物、小分子、CAR-T疗法等多种类型，有望在不远的未来迎来新突破。作为全球医药及生命科学行业创新的赋能者，药明康德也持续通过一体化、端到端的CRDMO平台，为全球合作伙伴提供赋能，助力重症肌无力等罕见肌肉疾病新药的开发，为患者带来更多突破性的治疗方案。回顾2025年上半年，重症肌无力疾病领域新药再次迎来多项新进展。5月，强生公司（Johnson & Johnson）宣布，美国FDA已批准其抗体疗法Imaavy（nipocalimab）上市，用于治疗抗AChR、抗MuSK抗体阳性的全身性重症肌无力（gMG）成人与12岁以上儿童患者。这是FDA批准的首个用于治疗该类患者群体的新生儿Fc受体（FcRn）阻断剂。这款疗法还被Evaluate列为今年有望上市的10大潜在重磅疗法之一。同月，翰森制药宣布其伊奈利珠单抗（inebilizumab）的新适应症上市申请获得中国NMPA受理，用于治疗全身性重症肌无力成人患者。这是一款靶向CD19 B细胞消耗性抗体，由翰森制药和安进（Amgen）共同开发。该药物的全球关键性3期试验MINT的结果于今年4月发表于《新英格兰医学杂志》。同样是5月，荣昌生物的BLyS/APRIL双靶点融合蛋白创新药物泰它西普在中国获批新适应症，用于治疗全身性重症肌无力成人患者。该产品可同时靶向B细胞激活因子（又称BLyS）和增殖诱导配体（APRIL），针对致病性抗体产生的源头——B细胞及浆细胞。此外，在CAR-T疗法领域，Cartesian Therapeutics于今年4月公布其在研mRNA细胞疗法Descartes-08用于治疗gMG的2b期研究的12个月数据。该研究早前已经取得积极结果，80%的可评估患者维持了临床显著应答达1年。Descartes-08是一款靶向BCMA的在研CAR-T细胞疗法，目前已启动3期临床研究，是MG领域目前研发进度较快的CAR-T细胞疗法，有望成为MG治疗领域首个细胞疗法。从这些进展可以看到，在重症肌无力治疗药物研发领域，2025年正在迎来多元化的新突破。图片来源：123RF过去十年间，至少7款重症肌无力新药获批上市重症肌无力是一种慢性的罕见自身免疫疾病，目前尚无治愈方法。该病的致病机制涉及患者体内的免疫球蛋白G（IgG）抗体，这些抗体会破坏神经与肌肉之间的突触传递，导致肌肉疲劳无力，进而导致极度疲劳和面部表情、言语、吞咽和活动困难，严重时甚至危及生命。大约85%的重症肌无力患者属于全身性重症肌无力（gMG）。根据2021年文献数据，gMG的患病率和发病率在全球范围内正在增加，全球患病率估计为每10万人中有2~36例。过去十年间，全球至少有7款重症肌无力新药获批上市，包括FcRn拮抗剂、补体抑制剂和B细胞耗竭剂等，为MG患者带来了更多治疗选择。C5补体抑制剂包括抗体和大环肽类药物，比如阿斯利康的ravulizumab（瑞利珠单抗）、eculizumab（依库珠单抗），以及优时比公司的大环肽类C5补体抑制剂zilucoplan（泽勒普肽）等，这类药物能够减少补体激活介导的神经肌肉接头损伤；FcRn抑制剂类药物以抗体为主，比如开头提到的强生公司的nipocalimab（尼卡利单抗），以及优时比公司的rozanolixizumab（罗泽利昔珠单抗）、Argenx和再鼎医药共同开发的efgartigimod（艾加莫德）等，它们可降低循环IgG抗体水平，从而减少致病抗体的循环，改善MG症状；B细胞耗竭剂类的代表药物为荣昌生物研发的BLyS/APRIL双靶点融合蛋白泰它西普，针对致病性抗体产生的源头——B细胞及浆细胞，减少致病性自身抗体的产生，发挥治疗作用。寻找“治愈”曙光，下一代重症肌无力疗法有望迎来新突破梳理公开资料可知，除了已获批的新药，全球范围内还有数十款新药正在临床阶段探索用于重症肌无力治疗的潜力，未来有望在多个方向取得新突破。在重症肌无力临床管线中，抗体类药物数量较多，包含单抗、双抗，以及一些抗体融合蛋白等，靶点涉及C5、FcRn、CD19/CD20等。例如阿斯利康在研的第三代C5补体抑制剂抗体gefurulimab已经进入3期临床阶段，其分子量小，具更好的渗透性，有望开发成为一款每周一次、由患者自行给药的皮下注射疗法。再如开头提到的抗CD19单抗伊奈利珠单抗，其翰森制药提交的针对重症肌无力的上市申请已获得中国NMPA受理，安进在两个月前也宣布了该产品治疗gMG成年患者的疗效与安全性的最新临床数据：每年两次给药的情况下，其在乙酰胆碱受体自身抗体阳性（AChR+）gMG患者中具有持久的疗效。CAR-T疗法也在临床研究中展现出“治愈”重症肌无力的潜力。CAR-T疗法近年来在自身免疫性疾病领域进展迅速，其可以使患者实现长期无药物缓解，被认为有望对重症肌无力的治疗产生潜在变革作用。在重症肌无力临床管线中，包括了十多款CAR-T疗法。这些在研管线以靶向B细胞或浆细胞为主，主要包括BCMA和CD19。在MG临床研发管线中，也有多款小分子药物。例如诺华在研的补体B因子口服抑制剂iptacopan（伊普可泮）和BTK抑制剂remibrutinib（瑞米布替尼），目前均已进入重症肌无力治疗研究3期临床阶段。再如NMD Pharma在研的氯离子通道（ClC-1）抑制剂NMD670正处于重症肌无力2b期临床阶段，该产品作用机制是针对骨骼肌的非免疫调节。多肽和核酸药物研发管线也有新突破。泽勒普肽（zilucoplan）作为首个获FDA批准用于治疗重症肌无力的每日一次经皮下给药的新型大环肽类C5补体抑制剂，是肽类药物在这一治疗领域的重要突破。除此之外，siRNA疗法cemdisiran联合抗体疗法pozelimab治疗重症肌无力的临床研究已处于3期阶段。前者由Alnylam公司和再生元（Regeneron）联合开发，作为一种靶向C5补体的RNAi疗法，cemdisiran在进入细胞后通过与靶标mRNA结合，从而使mRNA降解，避免功能性蛋白产生。Pozelimab是再生元开发的新一代C5补体抑制剂，此前已获FDA批准用于CD55缺陷型蛋白丢失性肠病。再生元正在开发这一C5抑制剂“抗体+siRNA”组合疗法以治疗包括重症肌无力在内的补体介导的疾病。其中，cemdisiran可以减少C5的产生，pozelimab可以阻断剩余C5的功能，二者共同抑制终端补体活性，有望在较低剂量下达到完全、持续的C5抑制，减少给药频率，并且皮下给药方便临床应用。值得一提的是，cemdisiran使用的GalNAc递送技术，是当下核酸疗法尤其是siRNA递送到肝细胞的主要策略。迄今FDA批准的7款siRNA疗法中，6款均使用了这项技术。也得益于此类递送技术的持续革新，纵览全球，siRNA疗法研发蓬勃发展，在研管线已超过350款。在这一产业新兴的趋势下，围绕GalNAc等复杂分子，药明康德旗下专注于寡核苷酸和多肽及相关化学偶联药物的WuXi TIDES平台已打造了涵盖定制合成、工艺开发及生产的一站式服务平台，更好地满足全球合作伙伴的寡核苷酸及各类化学偶联物的研发需求。公开信息显示，在定制化GalNAc方面，WuXi TIDES团队已经生产过涵盖不同类型、总数超过100款的GalNAc化合物，覆盖不同类型的GalNAc分子；通过优化GalNAc树脂负载工艺，将固相合成的收率提高50%。同时，借助流动化学平台，加速高纯度GalNAc的规模化生产。在疾病的征程上，科学与技术探索的步伐从未停歇。作为创新的赋能者、客户信赖的合作伙伴以及全球健康产业的贡献者，药明康德也将持续以独特的CRDMO业务模式，助力全球合作伙伴开发包括重症肌无力在内的更多疾病领域的创新疗法，持续造福病患！参考资料：[1]Binks, S.N.M., Morse, I.M., Ashraghi, M. et al. Myasthenia gravis in 2025: five new things and four hopes for the future. J Neurol 272, 226 (2025). https://doi.org/10.1007/s00415-025-12922-7[2]Dresser L., Wlodarski, R., Rezania, K., & Soliven, B. (2021). Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. J Clin Med, 10(11):2235.[3]Bubuioc, A. M., Kudebayeva, A., Turuspekova, S., Lisnic, V., & Leone, M. A. (2021). The epidemiology of myasthenia gravis. Journal of Medicine and Life, 14(1):7-16.版权说明：本文欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权或其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

细胞疗法上市批准免疫疗法临床3期信使RNA

2025-05-31

·PipelineReview

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

FREDERICK, MD, USA I May 30, 2025 I Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG). Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA). Descartes-08 is designed to be administered without preconditioning chemotherapy in an outpatient setting and does not use integrating vectors. “With the first participant now successfully enrolled, commencement of our Phase 3 AURORA trial represents a significant milestone in our mission to deliver a differentiated, durable treatment option to patients with MG,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. “With sustained benefits observed through 12 months in our Phase 2b trial, we believe Descartes-08 has the potential to transform the current MG treatment paradigm with just a single course of therapy.” “Marked by chronic use of steroids and other immunosuppressants while often delivering only limited efficacy, the current standard of care for patients with MG is inadequate,” said James (Chip) F. Howard, Jr., M.D., Cartesian Clinical Advisor and Professor of Neurology, Medicine, and Allied Health at the University of North Carolina School of Medicine. “Supported by compelling results from the Phase 2b trial, I firmly believe that Descartes-08 has the potential to serve as a safe, flexible, and durable treatment option for patients with MG. I look forward to helping advance this important study.” The Phase 3 AURORA trial is designed to assess Descartes-08 versus placebo (1:1 randomization) administered as six once-weekly outpatient infusions without preconditioning chemotherapy in approximately 100 participants with acetylcholine receptor autoantibody positive (AChR Ab+) MG. The primary endpoint will assess the proportion of Descartes-08 participants with an improvement in MG Activities of Daily Living (MG-ADL) score of three points or more at Month 4 compared to placebo. In April 2025, the Company announced updated efficacy and safety data from the Phase 2b trial of Descartes-08 in participants with MG. After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in the MG-ADL score at Month 12. The deepest and most compelling sustained responses were observed in Descartes-08-treated participants who did not have prior exposure to biologic therapies, with an average 7.1-point reduction in MG-ADL and 57% of patients in this subgroup maintaining minimum symptom expression at Month 12. The safety profile of Descartes-08 was consistent with previously reported data and continues to support outpatient administration. About Cartesian Therapeutics Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X , formerly known as Twitter. SOURCE: Cartesian Therapeutics

细胞疗法临床2期临床3期临床结果免疫疗法

100 项与 Descartes-08 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
重症肌无力	临床3期	美国	Cartesian Therapeutics, Inc.	2025-05-06
重症肌无力	临床3期	土耳其	Cartesian Therapeutics, Inc.	2025-05-06
抗中性粒细胞胞质抗体相关性血管炎	临床2期	-	Cartesian Therapeutics, Inc.	2025-12-01
皮肌炎	临床2期	-	Cartesian Therapeutics, Inc.	2025-12-01
系统性红斑狼疮	临床2期	美国	Cartesian Therapeutics, Inc.	2024-02-12
多发性骨髓瘤	临床2期	美国	Cartesian Therapeutics, Inc.	2021-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04146051 (Company_Website) 人工标引	临床2期	重症肌无力	36	Descartes-08	壓積廠鹹觸廠鬱網遞膚(膚遞繭顧艱製積鏇遞憲) = 衊構獵鹹鬱齋積襯獵簾膚觸觸鏇選壓鑰夢製鬱 (簾衊壓衊醖衊膚廠鏇蓋, 1.1) 更多	积极	2025-04-08
				Descartes-08 (without prior biologic therapies)	壓積廠鹹觸廠鬱網遞膚(膚遞繭顧艱製積鏇遞憲) = 廠餘襯夢餘鑰淵餘觸窪膚觸觸鏇選壓鑰夢製鬱 (簾衊壓衊醖衊膚廠鏇蓋, 1.5) 更多
NCT04146051 (MG-001, Neurology \| AAN2025) 人工标引	临床2期	重症肌无力	31	Descartes-08	鏇鏇簾淵繭範願齋鹹淵(簾鏇鬱夢獵範鏇積餘積) = 糧鹽簾網鏇選齋網網鬱襯餘築夢憲繭選齋鹹積 (範構選餘觸選壓觸蓋鑰 ) 更多	积极	2025-04-07
				Placebo	鏇鏇簾淵繭範願齋鹹淵(簾鏇鬱夢獵範鏇積餘積) = 壓鹽餘願構淵積淵觸顧襯餘築夢憲繭選齋鹹積 (範構選餘觸選壓觸蓋鑰 ) 更多
NCT04146051 (Company_Website) 人工标引	临床2期	重症肌无力	36	Descartes-08	鏇鏇獵淵餘餘製窪觸繭(顧蓋餘憲鑰範憲艱鹽觸) = 糧憲範築廠壓顧鏇願糧衊繭膚鹽齋網製憲選顧 (遞齋簾襯廠鑰齋艱膚憲 ) 更多	积极	2024-12-03
				Descartes-08 (without prior exposure to biologic therapies)	鏇鏇獵淵餘餘製窪觸繭(顧蓋餘憲鑰範憲艱鹽觸) = 鬱鹹鑰顧衊觸製鹹觸構衊繭膚鹽齋網製憲選顧 (遞齋簾襯廠鑰齋艱膚憲 ) 更多
NCT04816526 (CTgov)	临床2期	多发性骨髓瘤	13	Descartes 08	蓋構壓淵鹽蓋餘糧鹹鹹 = 襯鹹簾窪簾願衊衊廠廠壓築膚廠鑰製構襯憲餘 (網齋鬱鹹鏇鬱鹽網範糧, 餘構憲艱艱遞選餘襯廠 ~ 壓積獵簾憲壓構觸艱遞) 更多	-	2024-10-08
NCT04146051 (Biospace) 人工标引	临床2期	重症肌无力	36	Descartes-08	鏇網積衊夢艱網築築鬱(繭鹹壓夢醖構願衊壓網) = 糧製築餘廠繭廠齋鹽齋糧齋鹽築衊餘簾鹹選艱 (艱膚淵簾餘範鹹齋鹽壓 ) 达到更多	积极	2024-07-02
				Placebo	鏇網積衊夢艱網築築鬱(繭鹹壓夢醖構願衊壓網) = 繭夢獵淵壓襯膚齋淵衊糧齋鹽築衊餘簾鹹選艱 (艱膚淵簾餘範鹹齋鹽壓 ) 达到更多
Corporate Publications 人工标引	临床2期	重症肌无力	7	Descartes-08	鹽顧鏇蓋鹹鏇獵淵糧製(製築簾鏇鹹憲餘夢繭鹽) = 膚積構鹽顧獵繭範簾醖選膚膚餘構製憲襯遞憲 (製顧窪廠鏇網衊膚繭範 ) 更多	积极	2024-01-08
NCT04146051 (MG-001, Pubmed 1 \| Pubmed 2 \| Lancet Neurol) 人工标引	临床1/2期	重症肌无力	14	Descartes-08	範鑰鹹鑰憲窪齋齋選淵(餘衊鑰淵襯製鬱鹹糧範) = 淵鑰蓋夢糧鑰製遞選壓艱鹽鏇構艱窪鏇鹽艱遞 (顧積鬱積獵鑰顧鏇餘獵 ) 更多	积极	2023-07-01
NCT04146051 (Corporate Publications) 人工标引	临床1/2期	重症肌无力	2	Descartes 08	鑰窪簾觸窪遞餘選積觸(鹹艱憲構築餘齋願襯襯) = over 50% three months after Descartes-08 administration. 鹹遞壓製構鏇顧襯範膚 (選襯範艱鬱選壓夢顧廠 )	积极	2022-05-10